Literature DB >> 1371233

The relationship of prostate-specific antigen to digital rectal examination and transrectal ultrasonography. Findings of the American Cancer Society National Prostate Cancer Detection Project.

R J Babaian1, C Mettlin, R Kane, G P Murphy, F Lee, J R Drago, A Chesley.   

Abstract

The participating institutions of the American Cancer Society National Prostate Cancer Detection Project did 520 biopsies on 2425 men over a 3.5-year period. A total of 88 cancers were confirmed pathologically, 93% of which clinically were organ confined. In 324 men (62.3%), a recommendation for biopsy was made based solely on the results of transrectal ultrasonography (TRUS); in 69 patients (13.3%), solely on the digital rectal examination (DRE); in 116 patients (22.3%), on abnormal DRE and TRUS examinations; and in 11 patients (2.1%), in whom DRE and TRUS were normal, on elevated prostate-specific antigen (PSA) levels. The TRUS was abnormal in 80.6% of men found to have cancer, and the PSA level and DRE were abnormal for 67% and 50% of cancers, respectively. The influence of PSA level on cancer detection increased as the serum level increased above 4 ng/ml. The positive predictive values of both the DRE and TRUS were influenced significantly by the presence of an elevated PSA level (P = 0.044 and P less than 0.001, respectively). The results of this ongoing multicenter study support the following statements: (1) the prostate cancer detection rate is influenced by this diagnostic triad and (2) the detection rate of organ-confined disease can be improved substantially by early detection programs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1371233     DOI: 10.1002/cncr.2820690521

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

1.  PSA screening: the bottom line.

Authors:  M M Elhilali
Journal:  CMAJ       Date:  2000-03-21       Impact factor: 8.262

2.  Utility of volume adjusted prostate specific antigen density in the diagnosis of prostate cancer in Arab men.

Authors:  M Sheikh; O Al-Saeed; E O Kehinde; T Sinan; J T Anim; Y Ali
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

3.  Controversy in clinical cancer screening--prostate-specific antigen.

Authors:  D A McKay
Journal:  West J Med       Date:  1994-07

4.  The value of prostatic specific antigen density in the early diagnosis of prostate cancer.

Authors:  Ch Deliveliotis; G Louras; P Kyriazis; A Gyftopoulos; L Louka; E Alargof
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

5.  Potential clinical importance of the activation peptide of prostate-specific antigen.

Authors:  Laura M Voeghtly; Ida B Thøgersen; Zuzana Valnickova; Kristian W Sanggaard; Charleen T Chu; Tim D Oury; Jan J Enghild
Journal:  Int J Clin Exp Pathol       Date:  2009-06-20

Review 6.  Screening for prostate cancer.

Authors:  M L Cher; P R Carroll
Journal:  West J Med       Date:  1995-03

7.  Lifetime total and beverage specific--alcohol intake and prostate cancer risk: a case-control study.

Authors:  Maddalena Barba; Susan E McCann; Holger J Schünemann; Saverio Stranges; Barbara Fuhrman; Sabino De Placido; Giuseppe Carruba; Jo L Freudenheim; Maurizio Trevisan; Marcia Russell; Tom Nochajski; Paola Muti
Journal:  Nutr J       Date:  2004-12-09       Impact factor: 3.271

8.  Are hypoechoic lesions on transrectal ultrasonography a marker for clinically significant prostate cancer?

Authors:  Tae Il Noh; Yoon Sun Shin; Ji Sung Shim; Jong Hyun Yoon; Jae Heon Kim; Jae Hyun Bae; Du Geon Moon; Jae Young Park
Journal:  Korean J Urol       Date:  2013-10-15

Review 9.  Imaging in genitourinary cancer from the urologists' perspective.

Authors:  P Tsakiris; J de la Rosette
Journal:  Cancer Imaging       Date:  2007-05-28       Impact factor: 3.909

10.  Prostate-specific antigen testing accuracy in community practice.

Authors:  Richard M Hoffman; Frank D Gilliland; Meg Adams-Cameron; William C Hunt; Charles R Key
Journal:  BMC Fam Pract       Date:  2002-10-24       Impact factor: 2.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.